[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Resideo Technologies, Inc. (NYSE: REZI) filed an 8-K on 5 Aug 2025 to disclose two matters:

• Item 2.02 – Earnings: The company furnished (not filed) its Q2 2025 earnings press release as Exhibit 99. No financial figures are included in the filing; investors must consult the attached release for revenue, EPS or guidance details. Because the information is furnished, it is not subject to Exchange Act Section 18 liability and will not be incorporated by reference into other SEC documents.
• Item 5.07 – Say-on-Pay Frequency: At the 4 Jun 2025 Annual Meeting, 94.4% of votes favored holding advisory votes on executive compensation annually. On 31 Jul 2025, the Board accepted that preference and confirmed it will continue annual advisory votes going forward.

No other material transactions, financial statements or management changes were reported. Exhibit 104 contains the cover-page Inline XBRL data.

Positive

• Board confirms annual advisory votes, demonstrating responsiveness to 94.4% shareholder support and reinforcing good corporate governance.

Negative

• None.

Insights

Financial Analyst

TL;DR: Procedural 8-K; earnings press release furnished, board aligns with shareholder preference—limited market impact.

The filing is largely administrative. The Q2 2025 earnings details are referenced but not disclosed, so investors must await the press release for quantitative insight. Furnishing rather than filing limits legal exposure. Governance-wise, a 94.4% vote for annual say-on-pay is strong; the Board’s decision to comply maintains shareholder alignment and should be viewed positively, albeit routine. Absent financial metrics or strategic actions, the disclosure is unlikely to affect valuation or trading volumes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kolbeck Roland Wilhelm

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/01/2025		A		145,500		(2)	(2)	Common Stock	145,500	$0	145,500	D
Employee Stock Option (right to buy)	$1.53	08/01/2025		A		510,000		(3)	07/31/2035	Common Stock	510,000	$0	510,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

3. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

When did Resideo (REZI) release its Q2 2025 earnings?

The earnings press release was issued on August 5, 2025 and is attached as Exhibit 99.

What items are covered in Resideos August 5, 2025 8-K?

Item 2.02 (Results of Operations – earnings press release) and Item 5.07 (say-on-pay frequency vote outcome).

How did shareholders vote on the frequency of executive compensation advisory votes?

94.4% of shares voted favored conducting the advisory vote annually.

What decision did the Board make regarding future say-on-pay votes?

On July 31, 2025 the Board decided to continue holding the advisory vote on executive compensation every year.

Is the Q2 2025 earnings information considered 'filed' with the SEC?

No. It is furnished under Item 2.02, meaning it is not subject to Section 18 liability and is excluded from other filings by reference.